This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%
by Zacks Equity Research
Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.
Merck Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '25 View
by Zacks Equity Research
MRK posts encouraging Q4 results. However, the decision to temporarily halt shipments of Gardasil vaccines to China has affected its 2025 sales forecast.
PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor
by Zacks Equity Research
A Bloomberg article suggests activist investor Starboard cut Pfizer some slack by not nominating any director on the company's board this year.
Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)
by Zacks Equity Research
Erasca (ERAS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
by Zacks Equity Research
The FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs chemotherapy in certain breast cancer patients.
Down -27.17% in 4 Weeks, Here's Why Erasca (ERAS) Looks Ripe for a Turnaround
by Zacks Equity Research
Erasca (ERAS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -24.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)
by Zacks Equity Research
Erasca (ERAS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -22.89% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)
by Zacks Equity Research
Erasca (ERAS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study
by Zacks Equity Research
Data from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain bladder cancer patients.
Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Erasca (ERAS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Should You Buy Erasca, Inc. (ERAS) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings
by Zacks Equity Research
Despite strength in Revio and Onso platforms, an increasing number of customers delaying instrument purchases is likely to have dampened PacBio's (PACB) top line in the first quarter.
Here's How Cresco Labs (CRLBF) is Placed Before Q1 Earnings
by Zacks Equity Research
Cresco Labs' (CRLBF) rationalization and optimization efforts are expected to have had a positive impact on the company's first-quarter margins, profitability and cash flow.
Should SNDL (SNDL) be in Your Portfolio Ahead of Q1 Earnings?
by Riya Anand
SNDL's (SNDL) first-quarter performance is expected to benefit from reduced cost expenses and expansion into the liquor retail segment.
Should You Buy Hims & Hers Health (HIMS) Ahead of Q1 Earnings?
by Urmimala Biswas
Hims & Hers Health's (HIMS) first-quarter earnings are expected to have benefited from its strategy of placing its solutions at attractive price points.
Strength in Kidney Care Likely to Aid DaVita's (DVA) Q1 Earnings
by Zacks Equity Research
Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the first quarter.
Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Erasca (ERAS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for April 23rd
by Zacks Equity Research
FSM, LPX and ERAS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 23, 2024.
New Strong Buy Stocks for April 23rd
by Zacks Equity Research
CQP, AL, FSM, ERAS and QUAD have been added to the Zacks Rank #1 (Strong Buy) List on April 23, 2024.
J&J (JNJ) Q2 Earnings & Sales Top, '23 View Upped, Stock Jumps
by Zacks Equity Research
J&J (JNJ) beats estimates for second-quarter earnings and sales. It raises full-year sales and earnings guidance.
Merck (MRK) Keytruda Advanced Cervical Cancer Study Meets Goal
by Zacks Equity Research
Interim data from a late-stage study, evaluating Merck's (MRK) Keytruda as a combination therapy, met one of its primary endpoints of progression-free survival.
Amarin (AMRN) Dips 16% on Layoff Plan & Preliminary Sales Miss
by Zacks Equity Research
Amarin (AMRN) decides to initiate a restructuring plan to maximize cash flow opportunities in the United States. It also reports preliminary product revenues of around $65 million in Q2.
Wall Street Analysts Predict a 126% Upside in Erasca, Inc. (ERAS): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 125.9% in Erasca, Inc. (ERAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why Erasca, Inc. (ERAS) Looks Ripe for Bottom Fishing
by Zacks Equity Research
Erasca, Inc. (ERAS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Wall Street Analysts See an 111% Upside in Erasca, Inc. (ERAS): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at an 111.1% upside potential for Erasca, Inc. (ERAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.